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genotypes in four districts show a signiﬁcantly different
distribution, Peshawar (P= 0.041), Charsadda (P= 0.015),
Mardan (P= 0.05), Sawabi (P= 0.040) and non signiﬁcant
in Nowshehra district (P= 0.06). Among the risk factors,
use of unsterile equipments for medication, barbers and
previous history of hospitalization are the main factors for
HCV transmission. Genotype 3a and 3b, 1a, 1b and 2a are
the common genotypes in North West Frontier Province.
Genotype 4, 5, and 6 were not found even in a single
sample.
There is a less awareness about the various mode of
transmission of HCV among the population. A predominant
number of them are considering interferon treatment as
vaccine for hepatitis B and C.
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Introduction: Chronic infection with HCV a major health
problem. Clinical management of chronic HCV dependent
on extent liver ﬁbrosis. Liver biopsy gold stander an
invasive procedure responsible for severe complications
and sample variability interpretation. Serum biomarkers for
inﬂammation/ﬁbrosis investigated to wave liver biopsy.
Aim: Diagnostic accuracy panel of Non-invasive serum
biomarkers for hepatic ﬁbrosis [Fibrosure, APRI score, Forn’s
score] versus liver biopsy.
Method: 20 HCV patients subjected for: APRI, Forn’s,
Fibrosure scores; PCR quantitative HCV-RNA; liver functions;
lipid proﬁle; CBC; ultrasound guided liver biopsy.
Results:
FORNS score; AUROC (0.917) with 95% CI (0.791 1.042)
for (fof1) vs. (f2f3f4) while (0.688) with 95% CI (0.464 0.91)
for (fof1f2) vs. (f3f4). Cutoff (>6.9) sensitivity for
signiﬁcant ﬁbrosis (f2f3f4) and extensive ﬁbrosis (f3f4)
were (100%) speciﬁcity (0%) with accuracy (40%) and (20%)
respectively.
APRI score; AUROC (0.792) with 95% CI (0.568 1.015)
comparing (f0f1) vs. (f2f3f4) while was (0.875) with 95%
CI (0.703 1.047) for (f0f1f2) vs. (f3f4). Cutoff (<0.5)
sensitivity (0%) and speciﬁcity (100%) with accuracy (60%)
for signiﬁcant ﬁbrosis and (80%) for extensive ﬁbrosis.
Fibrosure (ﬁbro-acti test); showed best AUROC (1.00) in
different ﬁbrotic stages with 95% CI (1.00 1.00). Cutoff
(>0.59) sensitivity (50%) for signiﬁcant ﬁbrosis and (100%)
for extensive ﬁbrosis while speciﬁcity (100%) in all ﬁbrotic
stages. The PPV (100%) for signiﬁcant and extensive
ﬁbrosis. NPV and accuracy (75%, 80%) respectively for
signiﬁcant ﬁbroses, while NPV and accuracy (100%) for
extensive ﬁbrosis.
Signiﬁcant correlation between liver biopsy and Fibro-test
(P 0.002) and Acti-test (P 0.000).
Signiﬁcant correlation between liver biopsy hepatitis
activity score andAPRI (P 0.047) and FORNS score (P 0.000).
Conclusion: FORNS score wasn’t considered since does not
discriminate between signiﬁcant and extensive ﬁbrosis. Low
sensitivity of APRI prohibtes detection of minmal ﬁbrosis
and allow undetermined results. Fibrosure classiﬁed all
cases of chronic HCV sufﬁcient to waive liver biopsy.
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Schistosomiasis is a term covering infestation of man by
blood ﬂuke trematode parasite. In Egypt, Schistosoma
mansoni occurs intensively in the Nile Delta, while
S. hematobium is endemic in Nile Valley. Studies in Egypt
found the highest risk of HCV infection in those infested
with schistosomiasis. HCV-Ab prevalence reported 70% in
adults suffering from Schistosomiasis and without history of
blood transfusion.
Aim: Determine the link between schistosomal infestation
and HCV, whether the parasite could be vector of
transmission of the virus to human.
Methods: Different stages of life cycle of S. mansoni
provided by Theodor Bilharz Institute.
Specimens of living S. mansoni worms and Biomphalaria
alexandria snails were grounded separately in sterile mortar
after adding 5ml sterile saline. After centrifugation sterile
supernatant tested for
• Detection of HCV-RNA by RT-PCR
• HCV-RNA quantitation.
Results:
• HCV-Antigen: Worms, Miracidia, Snails and Cercariae of
S. mansoni were positive for HCV-Ag. The snails gave
strong positive result. Eggs gave negative result.
• HCV-RNA by RT-PCR: Worms, Miracidia, Snails and
Cercariae of S. mansoni tested for HCV-RNA By Qualitative
RT-PCR were positive. The eggs gave negative result.
• HCV-RNA Quantitation: Miracidia were positive (800
copies/ml) and snails were positive (1100 copies/ml);
other specimens gave negative results.
Conclusions:
• Existence of virus and its replication in parasite
• S. mansoni parasite carries HCV and considered as a non-
human vector for transmission of HCV infection.
• Parasitic and viral co-infection change pathology of
hepatic schistosomiasis from periportal ﬁbrosis to cirrhosis
and the development of HCC.
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Background: Some genotype 1b HCV patients with high
HCVRNA load can not get satisfactory anti-virus response.
DFPP (double ﬁltration plasmapheresis) is a newly developed
biotechnology technique which can selectively removes high
molecular weight substances including HCV particles from
plasma. In this study, efﬁcacy and safety of DFPP plus anti-
virus therapy were studied and compared in treatment of
HCV patients.
Methods: 8 chronic genotype 1b HCV patients received
anti-virus therapy (IFN and ribavirin) at 8th day after
admission and each of them individually decided whether
to receive DFPP therapy. Then 8 weeks of observation were
performed.
Result: Only 1 patient decided to receive 5 times of DFPP
therapy (at 8th, 9th, 11th, 15th and 16st day after admission)
with anti-virus therapy and got satisfactory response at 29rd
day with liver function improving. Other patients did not
get the same satisfactory responses. HCVRNA degression
